Heyu Biological Technology Corp, a company engaged in the food trade and biotechnology sectors, has released its Form 10-Q report for the third quarter ended September 30, 2023. The report highlights the company's financial performance and operational developments during this period.
Financial Highlights
- Total Net Revenues: $78,204. The increase in revenue was primarily driven by expanding product variety and distribution network.
- Gross Profit: $(26,226). The company experienced a negative gross profit due to higher cost of revenues.
- Operating Loss: $(407,805). Operating loss increased due to higher general and administrative expenses.
- Net Loss: $(392,435). The net loss widened compared to the previous period.
- Loss per Share: $(0.00092). Reflects the increased net loss per share for the period.
Business Highlights
- Revenue Segments: The company's revenue for the three months ended September 30, 2023, was primarily driven by product sales, reflecting the early stages of Hongchang Group's business operations. The increase in revenue was attributed to expanding product variety and distribution networks both in China and overseas.
- Geographical Performance: The company is focusing on expanding its distribution network in China and overseas, which is expected to drive future revenue growth.
- New Production Launches: The Hongchang Food Industrial Park, a significant project under construction, is expected to complete by 2024. This facility will enhance the company's capacity in food trade and biotechnology.
- Future Outlook: The company anticipates continued growth through the expansion of its product lines and distribution networks. The completion of the Hongchang Food Industrial Park is expected to significantly boost operational capabilities.
SEC Filing: